At Retinal and Ophthalmic Consultants, we are actively participating in many national clinical research trials. The efforts of our physicians, staff, and patients have led to the approval of several treatments that are now considered to be the standard of care. Involvement in clinical research offers our patients access to new and potentially superior treatments to patients with sight-threatening conditions, such as macular degeneration and diabetic retinopathy.
Our research staff is certified in all areas required such as photography, phlebotomy, ETDRS and EVA vision testing. In the future, we hope to expand the scope of our studies to include other subspecialties such as glaucoma and oculoplastics.
Click on the links below for more information on each study.
TOGA-01 Phase 2/3
A Randomized, Double Masked, Placebo Controlled
Study Evaluating ORACEA® in Subjects with
Geographic Atrophy Secondary to Non-Exudative
Age-Related Macular Degeneration IND#117302 Sponsor: Univ.Of Virginia
OHR pharmaceuticals MAKO
Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
Phase 2, double-masked, randomized, multiple-dose, regimen-rangingstudy of efficacy and safety of intravitreal REGN2176-3 in patients with AMD
Genentech- Lampalizamaub GX29185 SPECTRI-
A phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration.
DRCR.net Protocol V-
Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity
Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15MG Once Daily or 15MG Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy
Click here to view the Clinical Sudy Protocol
DRCR.net Diabetic Retinopathy Clinical Research Network Protocol W
Intravitreous Anti-VEGF Treatment for Prevention of Visions Threatening Diabetic Retinopathy in Eyes at High Risk
Ocriplasmin Research to Better Inform Treatment (ORBIT)PROTOCOL NUMBER:TG-MV-018. PHASE 4.
CORE2 NIH-National Eye Institute, National Institutes of Health. Department of Health and Human Services / Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
A Multicenter, Prospective, Randomized, Phase III, Non-Inferiority Trial of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks Versus Intravitreal Aflibercept Every 4 Weeks
A phase 2, multi-centre, randomised, double-masked, placebocontrolled,parallel-group study to investigate the safety,tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
DE-109 for theTreatment of active, Non-Infectious Uveitis
A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista™ (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.
A phase 2, multi-centre, randomised,doublemasked,placebocontrolled,parallel-group study toinvestigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye
RegenerMD-1124-on A (Protocol No. 32-007)
An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration
DRCR protocol S
Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy.
VEGF Trap-Eye in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion
Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion.
VIEW 1 EXTENSION
study of intravitreal
VEGF Trap-Eye in neovascular age-related macular degeneration
PDE5 inhibitor exposure in men with erectile dysfunction increases the risk for the development of non-arteritic anterior ischemic optic neuropathy (NAION).
HORIZON - Principal Investigator
(CNV) secondary to age-related macular degeneration (AMD) or macular edema secondary to retinal vein occlusion (RVO) who have completed a Genentech-sponsored ranizumab study.
VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO).
study of the efficacy and safety of 0.5 mg and 2.0 mg Ranibizumab; administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration.
VEGF Trap-Eye in patients with diabetic macular edema (DME).
Three (3) year multi-center study with monthly visits for patients with diabetic macular edema comparing Lucentis with Standard of Care Laser treatments.
One (1) year multi-center study with monthly visits comparing Lucentis to sham procedure for patients with central retinal vein occlusion.
comparing VEGF-Trap against Lucentis for patients with newly-diagnosed age-related macular degeneration.
study comparing Sirna against Lucentis for age-related macular degeneration
NOTAL VISION HMP-V4
Sensitivity of the Home Macular Perimeter (HMP) in detection of choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD).
NOTAL VISION HMP-V4
Lucentis in newly-diagnosed and previously-treated subjects with age-related macular degeneration.
Please call 609.646.5200 ext 239 for more information and participation criteria in our active/enrolling clinical trials.